ArticleCureus2026
Rash-Negative Dermatomyositis-Spectrum Overlap Myositis With PM/Scl Positivity Presenting With Progressive Pharyngeal Dysphagia.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dermatomyositis-spectrum inflammatory myopathy may present without characteristic cutaneous findings, and overlap phenotypes can delay recognition when early neuromuscular examination is not yet diagnostic. We describe the case of a patient with rheumatology-diagnosed dermatomyositis without rash and PM/Scl-positive overlap myositis with systemic sclerosis features whose course was marked by interstitial lung disease, progressive weakness, and objectively confirmed pharyngeal dysphagia. A 64-year-old female with interstitial lung disease presented with several weeks of polyarthralgia, severe fatigue, and marked muscle enzyme elevation. Initial examination showed no rash, sclerodactyly, or proximal weakness. Laboratory evaluation demonstrated a creatine kinase level of 12,810 U/L, elevated transaminases, a high-titer antinuclear antibody, positive PM/Scl-100 and PM/Scl-75 antibodies, and a weakly positive Mi-2 antibody. She was diagnosed with dermatomyositis without rash and PM/Scl-positive overlap myositis with systemic sclerosis features and treated with prednisone, mycophenolate mofetil, hydroxychloroquine, and antimicrobial prophylaxis. Intravenous immunoglobulin (IVIG) was recommended but was not initially approved. Her course progressed to severe weakness and dysphagia, ultimately preventing oral medication administration. During hospitalization, a videofluoroscopic swallow evaluation demonstrated aspiration with thin liquids and pharyngeal phase dysphagia. She received IVIG, with subsequent improvement in swallowing and functional status. This report highlights the importance of an overlap-informed approach to inflammatory myopathy when classic cutaneous features are absent. Progressive dysphagia should be treated as a marker of severe disease because it increases the risk of aspiration, contributes to malnutrition, and may prevent the administration of oral immunosuppressive therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.